This study consists of two experiments conducted to explore a toxicological comparison between tobramycin sulphate and amikacin sulphate, and to explore the role of calcium gluconate in antagonizing or reducing the main toxic side effects of tobramycin and amikacin like nephrotoxicity, ototoxicity and neuromuscular blockade.The first experiment was designed to study and measure the acute toxicity of these drugs by using the Up and Down method, which showed that the value of intravenous LD50 of both drugs increased almost twice as much from 154.8 to 294.8 mg/kg for tobramycin and from 437.1 to 737.1 mg/kg for amikacin after the pretreatment with calcium gluconate.The second experiment was performed on rabbits injected with selected toxic dose considered as LD50 of tobramycin and amikacin given by intravenous IV route for the observation of the neurotoxicity signs and recording their appearance time, until the observation of certain definite neurotoxic signs such as loss of righting reflex. At that time, calcium gluconate was given by slow intravenous infusion (over 5-10 minutes) at a high range of therapeutic dose 45mg/kg and the time of disappearance of neuromuscular blockade signs with the number of life and dead animal were recorded for each treatment.The results of this experiment showed that although tobramycin was more potent in inducing neurotoxic effects according to the dose used but amikacin is seems to be more efficacious in developing neurotoxic signs response according to it is short appearance and disappearance time of toxic signs after amikacin and calcium treatment, in comparison with that of tobramycin and calcium treatment.
Introduction
Aminoglycoside (AG) antibiotics are highly potent bactericidal antibiotics with many desirable properties that have been used in hospital settings for many years, alone or in combination with other antibiotics, to combat severe aerobic gramnegative bacterial infections caused by resistant microorganisms to less toxic antibiotics. Amikacin has the broadest spectrum of activity and was developed from kanamycin in 1976 and it is the first less toxic alternative to the older aminoglycosides.
Tobramycin is an aminoglycoside obtained from cultures of Streptomyces tenebrarius it was approved by the FDA in 1975 (1, 5) .There are abundant evidences that repeated administration of all aminoglycoside such as amikacin and tobramycin to experimental animals results in increased urinary excretion of divalent cations.
Hypercalciuria is the most frequently reported finding, (2, 9, 16) . Neuromuscular Blockade: Amikacin and tobramycin are capable of causing neuromuscular blocking effect and result from interfering with acetylcholine release (presynaptic) and/or reducing response to acetylcholine (postsynaptic) (4) .Death occurs due to neuromuscular blocking and respiratory paralysis has been reported in cats receiving high dose of amikacin, this indicate presence of strong relation-ship between neuromuscular blocking effect and acute toxicity represented by LD 50 . (7) Mechanism of Neuromuscular Blockade: These drugs interfere with calcium ions movement through the calcium channels of the membrane of motor nerve ending inhibiting acetylcholine release at the synaptic cleft. (16) .In a study done by (3) AL-Qadisiya Journal of Vet.Med.Sci.
Vol./12
No./2 2013 ______________________________________________________________________________ they did a comparative evaluation of neuromuscular blocking effect between amikacin and tobramycin by using of sciatic nerve-gastronemius muscle and the results showed that tobramycin potency was higher than amikacin in inducing this effect.Clinical signs of intoxication included convulsions, prostration, polydipsia, dyspnea and ataxia, dogs exhibited muscle tremors, salivation, and anorexia (9).In a study undertaken by (8) , indicated the variation in the tolerance of mice to a single lethal dose of amikacin. Female mice placed in cages providing constant thermal conditions and lighted for 8-20 hrs were given a single intraperitonial injection of 1.6 to 1.9 g/kg amikacin in different times over the 24 hours (8h, 14h, 20h, and 2 h). The number of the dead mice was determined every day, for seven consecutive days. The mortality rate was influenced by time of administration of amikacin and toxicity exhibited a peak at 2 h (mean 60%) and (mean 47.7%) at 14 hr.Clinical signs of intoxication in rodents included convulsions, prostration, polydipsia, dyspnea and ataxia. Dogs exhibited muscle tremors, salivation, and anorexia. Histopathological examination of kidneys from dogs died up to 13 days after dosing revealed necrosis of the proximal convoluted tubule (9, 15).
Biological Relationship between Aminoglycoside and Calcium:
The aminoglycoside antibiotics, such as amikacin and tobramycin, have the potential to induce disturbances of electrolyte homeostasis characterized by hypomagnesaemia and hypocalcaemia (11) . These studies have all documented inappropriately high levels of urinary electrolyte excretion for the prevailing low plasma concentrations, indicating a failure of the kidneys to adequately conserve cations, especially calcium and magnesium.There is abundant evidence that repeated administration of gentamicin to experimental animals results in increased urinary excretion of divalent cations. Hypercalciuria is the most frequently reported finding (4, 6, 13) , although hypermagnesiuria has also been reported.Some reports have focused on the interaction between aminoglycosides and calcium in the kidney. (12and 11) reported that calcium inhibits the binding of aminoglycosides to the renal plasma membranes, and that oral calcium loading protects against aminoglycoside nephrotoxicity.(14) also found that dietary calcium loading attenuates the severity of gentamicin nephrotoxicity in rats. In addition, it has been shown that the hypercalciuria induced by administration of gentamicin occurs with accompanying nephrotoxicity.In those studies that carried out by (4) to explore the role of calcium in reducing the toxic side effect of gentamicin in rats, he found that acute toxicity minimized to the half when calcium gluconate was intraperitonialy administered before the drug because the median lethal dose (LD50) changed from 345 to 645 mg/kg. He concluded that there was a parallel competitive inhihibitory effect between gentamicin and calcium.In studies by (9) he concluded from all his experiments that calcium play important role in antagonizing the side effects of gentamicin when given alone or mixed with gentamicin, and had no effect on gentamicin antibacterial activity. (15) Thirty-two male rabbits were used. They were divided according to drug treatment (8 rabbits in each treatment), in which one rabbit was used for each dose. Different lethal doses of both amikacin and tobramycin were used by intravenous route, while calcium administration was carried out by intraperitoneal route about 15 minutes prior to amikacin or tobramycin administration. Lethality was recorded for each group after 24 hrs and LD 50 were calculated according to the Up and Down method (Dixon 1980 This experiment was performed on rabbits, and both drugs, amikacin and tobramycin, were given by intravenous infusion (slow infusion) until the signs of neuromuscular blockade which are represented by the head and ears dropping as critical signs of paralysis. Five rabbits were used for each treatment with selected toxic dose of amikacin and tobramycin according to their LD 50 and route used, (437.1 mg /kg) and (154.8mg/kg) for both drugs respectively. These treatments were used for observation of the of neurotoxic signs and recording their appearance time, until the observation of certain definite neuromuscular toxic sign represented by loss of righting reflex at that time calcium gluconate were given by intravenous infusion at high range of therapeutic dose 45 mg/kg. The time of appearance and disappearance of neuromuscular blockade signs with the number of life and dead animals were recorded for each treatment.
Results

First Experiment:-Acute Toxicity
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Discussion
The results of the acute toxicity experiment showed that the value of IV LD 50 of amikacin was more than that of tobramycin, which means that amikacin safer than tobramycin, while a pretreatment with calcium gluconate led to decrease the acute toxicity nearly to the half since the values LD 50 of both drugs increased almost twice to that of their LD 50 values when given alone. This led to the conclusion that there is some competition between these antibiotics and calcium ions at the cellular level transport system.The results of the acute toxicity study were in accordance with studies carried out by AL-Hamiree (2) who confirmed the presence of linear and parallel-dose relationship of acute toxicity for gentamicin and calcium gluconate. In the second experiment the findings indicate that calcium can reverse or prevent an aminoglycoside -mediated neuromuscular blockade.Tobramycin seems to be more potent than amikacin in inducing toxic effects according to LD50 results of acute toxicity. However the results of neuromuscular blockade effect of both antibiotics showed that amikacin is more efficacious in developing response (neurotoxic signs) than tobramycin accordingly to the time of appearance of these signs which were in short time, within few minutes, this led to the failure of calcium therapy if it is not administered at once but the successful one led to complete recovery of the rabbit and disappearance of all neurotoxic signs. The time of disappearance of these toxic signs with amikacin is much faster than tobramycin treated animal.This may be attributed to the structural differences between the two antibiotics which may lead to rapid transport of amikacin through nerve membrane that differ structurally from kidney and ear cell. In addition the mechanism of neuromuscular toxicity differ from that of nephrotoxic and ototoxic effect, since it included acetyl choline being released according to the rapidness of aminoglycoside transport through nerve cell and availability of calcium within AL-Qadisiya Journal of Vet.Med.Sci.
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No./2 2013 ______________________________________________________________________________ 117 neuron.The results come in agreement with other studies by Al-Hamiree (2) who treated rabbits with a toxic dose of gentamicin (100mg/kg) into the ear vein by IV infusion. After one minute, the neurotoxic signs appeared which were represented by loss of balance, unsteady gait, limb paralysis, head and ear dropping, after the appearance of these signs a therapeutic dose of calcium administered and led to disappearance of these signs and the animals return to normal condition within 3 minutes.In a study by Renna et.al., (3) a comparative evaluation of neuromuscular blocking effect between amikacin and tobramycin was carried out by using of sciatic nerve gastronemius muscle. They showed that tobramycin potency is higher than amikacin in inducing this effect.According to neuromuscular blockade results, it seems that tobramycin is more potent neurotoxic drug according to the dose used but amikacin is more efficacious in developing toxic response this may be due to the differences in antibiotics and nerve cells structure as well as the mechanism of neuromuscular blockade that include acetylcholine and calcium availability.Pretreatment of these drugs with calcium gave complete protection with amikacin and complete to partial protection with tobramycin, both drugs exhibit a dose response nephrotoxicity relationship with treatment periods.From the acquired results it is recommend that calcium be given as combination treatment either alone or as new formulating drug to reduce tobramycin, amikacin or other aminoglycoside toxic side effects.
